• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Dyne Therapeutics Inc. (Amendment)

    2/12/24 4:06:32 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DYN alert in real time by email
    SC 13G/A 1 d760535dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 2)*

     

     

    Dyne Therapeutics, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    26818M108

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    Page 1 of 15


    CUSIP No. 26818M108

     

     1.   

     Name of Reporting Persons

     

     MPM BioVentures 2018, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     3,216,844

       6.  

     Shared Voting Power

     

     0

       7.  

     Sole Dispositive Power

     

     3,216,844

       8.  

     Shared Dispositive Power

     

     0 

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,216,844

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     4.0%

    12.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    Page 2 of 15


    CUSIP No. 26818M108

     

     1.   

     Name of Reporting Persons

     

     MPM BioVentures 2018 (B), L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     Germany

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     170,971

       6.  

     Shared Voting Power

     

     0

       7.  

     Sole Dispositive Power

     

     170,971

       8.  

     Shared Dispositive Power

     

     0 

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     170,971

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     0.2%

    12.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    Page 3 of 15


    CUSIP No. 26818M108

     

     1.   

     Name of Reporting Persons

     

     MPM Asset Management Investors BV2018 LLC

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     63,488

       6.  

     Shared Voting Power

     

     0

       7.  

     Sole Dispositive Power

     

     63,488

       8.  

     Shared Dispositive Power

     

     0 

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     63,488

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     0.1%

    12.  

     Type of Reporting Person (See Instructions)

     

     OO

     

    Page 4 of 15


    CUSIP No. 26818M108

     

     1.   

     Name of Reporting Persons

     

     MPM BioVentures 2018 GP LLC

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0

       6.  

     Shared Voting Power

     

     3,387,815*

       7.  

     Sole Dispositive Power

     

     0

       8.  

     Shared Dispositive Power

     

     3,387,815*

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,387,815*

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     4.2%

    12.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    *

    Consists of 3,216,844 shares held by MPM BioVentures 2018, L.P. (“BV 2018”) and 170,971 shares held by MPM BioVentures 2018(B), L.P. (“BV 2018(B)”). MPM BioVentures 2018 GP LLC (“BV 2018 GP”) and MPM BioVentures 2018 LLC (“BV 2018 LLC”) are the direct and indirect general partners of BV 2018 and BV 2018(B).

     

    Page 5 of 15


    CUSIP No. 26818M108

     

     1.   

     Name of Reporting Persons

     

     MPM BioVentures 2018 LLC

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0

       6.  

     Shared Voting Power

     

     3,451,303*

       7.  

     Sole Dispositive Power

     

     0

       8.  

     Shared Dispositive Power

     

     3,451,303*

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,451,303*

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     4.3%

    12.  

     Type of Reporting Person (See Instructions)

     

     OO

     

    *

    Consists of 3,216,844 shares held by BV 2018, 170,971 shares held by BV 2018(B) and 63,488 shares held by MPM Asset Management Investors BV2018 LLC (“AM BV 2018 LLC”). BV 2018 GP and BV 2018 LLC are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV 2018 LLC.

     

    Page 6 of 15


    CUSIP No. 26818M108

     

     1.   

     Name of Reporting Persons

     

     Luke Evnin

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0

       6.  

     Shared Voting Power

     

     3,451,303*

       7.  

     Sole Dispositive Power

     

     0

       8.  

     Shared Dispositive Power

     

     3,451,303*

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,451,303*

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     4.3%

    12.  

     Type of Reporting Person (See Instructions)

     

     IN

     

    *

    Consists of 3,216,844 shares held by BV 2018, 170,971 shares held by BV 2018(B) and 63,488 shares held by AM BV 2018 LLC. The Reporting Person is a managing director of BV 2018 LLC.

     

    Page 7 of 15


    CUSIP No. 26818M108

     

     1.   

     Name of Reporting Persons

     

     Ansbert Gadicke

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0

       6.  

     Shared Voting Power

     

     3,451,303*

       7.  

     Sole Dispositive Power

     

     0

       8.  

     Shared Dispositive Power

     

     3,451,303*

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,451,303*

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     4.3%

    12.  

     Type of Reporting Person (See Instructions)

     

     IN

     

    *

    Consists of 3,216,844 shares held by BV 2018, 170,971 shares held by BV 2018(B) and 63,488 shares held by AM BV 2018 LLC. The Reporting Person is a managing director of BV 2018 LLC.

     

    Page 8 of 15


    CUSIP No. 26818M108

     

     1.   

     Name of Reporting Persons

     

     Todd Foley

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0

       6.  

     Shared Voting Power

     

     3,451,303*

       7.  

     Sole Dispositive Power

     

     0

       8.  

     Shared Dispositive Power

     

     3,451,303*

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,451,303*

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     4.3%

    12.  

     Type of Reporting Person (See Instructions)

     

     IN

     

    *

    Consists of 3,216,844 shares held by BV 2018, 170,971 shares held by BV 2018(B) and 63,488 shares held by AM BV 2018 LLC. The Reporting Person is a managing director of BV 2018 LLC.

     

    Page 9 of 15


    Item 1.

      (a)

    Name of Issuer

    Dyne Therapeutics, Inc.

     

      (b)

    Address of Issuer’s Principal Executive Offices

    1560 Trapelo Road

    Waltham MA 02451

     

    Item 2.

     

      (a)

    Name of Person Filing

    MPM BioVentures 2018, L.P.

    MPM BioVentures 2018(B), L.P.

    MPM Asset Management Investors BV2018 LLC

    MPM BioVentures 2018 GP LLC

    MPM BioVentures 2018 LLC

    Luke Evnin

    Ansbert Gadicke

    Todd Foley

     

      (b)

    Address of Principal Business Office or, if none, Residence

    c/o MPM Capital LLC

    399 Boylston Street, Suite 1100

    Boston, MA 02116

     

      (c)

    Citizenship

    All entities were organized in Delaware. The individuals are all United States citizens.

     

      (d)

    Title of Class of Securities

    Common Stock

     

      (e)

    CUSIP Number

    26818M108

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable

     

    Page 10 of 15


    Item 4.

    Ownership

    The following ownership information is presented as of February 12, 2024.

     

    MPM Entity

       Shares
    Held
    Directly
         Sole Voting
    Power
         Shared
    Voting
    Power
         Sole
    Dispositive
    Power
         Shared
    Dispositive
    Power
         Beneficial
    Ownership
         Percentage
    of Class(4)
     

    BV 2018

         3,216,844        3,216,844        0        3,216,844        0        3,216,844        4.0 % 

    BV 2018(B)

         170,971        170,971        0        170,971        0        170,971        0.2 % 

    AM BV 2018 LLC

         63,488        63,488        0        63,488        0        63,488        0.1 % 

    BV 2018 GP(1)

         0        0        3,387,815        0        3,387,815        3,387,815        4.2 % 

    BV 2018 LLC(2)

         0        0        3,451,303        0        3,451,303        3,451,303        4.3 % 

    Luke Evnin(3)

         0        0        3,451,303        0        3,451,303        3,451,303        4.3 % 

    Ansbert Gadicke(3)

         0        0        3,451,303        0        3,451,303        3,451,303        4.3 % 

    Todd Foley(3)

         0        0        3,451,303        0        3,451,303        3,451,303        4.3 % 

     

    (1)

    Consists of 3,216,844 shares held by BV 2018 and 170,971 shares held by BV 2018(B). BV 2018 GP and BV 2018 LLC are the direct and indirect general partners of BV 2018 and BV 2018(B).

    (2)

    Consists of 3,216,844 shares held by BV 2018, 170,971 shares held by BV 2018(B) and 63,488 shares held by AM BV2018 LLC. BV 2018 GP and BV 2018 LLC are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018 LLC.

    (3)

    Consists of 3,216,844 shares held by BV 2018, 170,971 shares held by BV 2018(B) and 63,488 shares held by AM BV2018 LLC. The Reporting Person is a managing director of BV 2018 LLC.

    (4)

    Percentage ownership is based on 81,106,148 shares outstanding as of January 11, 2024, as disclosed in the Issuer’s prospectus supplement dated January 4, 2024, filed with the Securities and Exchange Commission on January 5, 2024.

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not Applicable

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not Applicable

     

    Item 8.

    Identification and Classification of Members of the Group

    Not Applicable

     

    Item 9.

    Notice of Dissolution of a Group

    Not Applicable

     

    Item 10.

    Certification

    Not Applicable

     

    Page 11 of 15


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 12, 2024

    MPM BIOVENTURES 2018, L.P.

     

    By:   MPM BioVentures 2018 GP LLC,
      its General Partner
    By:   MPM BioVentures 2018 LLC,
      Its Managing Member
    By:  

    /s/ Luke Evnin

    Name:   Luke Evnin
    Title:   Managing Director
    MPM BIOVENTURES 2018 (B), L.P.
    By:   MPM BioVentures 2018 GP LLC,
      its General Partner
    By:   MPM BioVentures 2018 LLC,
      Its Managing Member
    By:  

    /s/ Luke Evnin

    Name:   Luke Evnin
    Title:   Managing Director
    MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
    By:   MPM BioVentures 2018 LLC,
      Its Manager
    By:  

    /s/ Luke Evnin

    Name:   Luke Evnin
    Title:   Managing Director
    MPM BIOVENTURES 2018 GP LLC
    By:   MPM BioVentures 2018 LLC,
      Its Managing Member
    By:  

    /s/ Luke Evnin

    Name:   Luke Evnin
    Title:   Managing Director

     

    Page 12 of 15


    MPM BIOVENTURES 2018 LLC
    By:  

    /s/ Luke Evnin

    Name:   Luke Evnin
    Title:   Managing Director
    By:  

    /s/ Todd Foley

    Name:   Todd Foley
    By:  

    /s/ Luke Evnin

    Name:   Luke Evnin
    By:  

    /s/ Ansbert Gadicke

    Name:   Ansbert Gadicke

    EXHIBITS

     

    A:

    Joint Filing Agreement

     

    Page 13 of 15

    Get the next $DYN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DYN

    DatePrice TargetRatingAnalyst
    12/10/2025$40.00Perform → Outperform
    Oppenheimer
    10/10/2025Outperform → Perform
    Oppenheimer
    8/25/2025$35.00Outperform → Strong Buy
    Raymond James
    6/24/2025$13.00Mkt Perform
    Bernstein
    6/11/2025$37.00Outperform
    Raymond James
    6/2/2025$34.00Outperform
    Oppenheimer
    5/29/2025$46.00Outperform
    Evercore ISI
    3/12/2025$50.00Outperform
    BMO Capital Markets
    More analyst ratings

    $DYN
    SEC Filings

    View All

    Dyne Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)

    1/12/26 7:35:31 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)

    12/23/25 7:35:24 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Dyne Therapeutics Inc.

    424B5 - Dyne Therapeutics, Inc. (0001818794) (Filer)

    12/10/25 4:31:58 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors

    BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the appointment of Carlo Incerti, M.D., to its Board of Directors, effective January 1, 2026. Dr. Incerti is a highly accomplished executive with a strong background in medicine and over 35 years of strategic experience in the biopharmaceutical industry. "Carlo's appointment comes at a pivotal moment for Sparrow as we are looking ahead to pivotal trials of clofutriben for type 2 diabetes and seeking to expand development into other cardiometabolic indications," said Robert Jacks, Sparrow President and Chief Executive Officer. "Carlo is respected globally for

    2/2/26 8:30:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1

    - Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE clinical trial - - Expect to complete enrollment in ACHIEVE Registrational Expansion Cohort in early Q2 2026 - WALTHAM, Mass., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted Orphan Drug designation for zeleciment basivarsen (z-basivarsen), for the treatment of myotonic muscular dystrophy type 1 (DM1)

    1/20/26 7:30:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

    WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 5:15 p.m. PT (8:15 p.m. ET). A live webcast will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 30 days. About Dyne TherapeuticsDyne Therapeutics i

    1/7/26 7:30:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dyne Therapeutics upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Dyne Therapeutics from Perform to Outperform and set a new price target of $40.00

    12/10/25 8:10:44 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics downgraded by Oppenheimer

    Oppenheimer downgraded Dyne Therapeutics from Outperform to Perform

    10/10/25 8:28:51 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics upgraded by Raymond James with a new price target

    Raymond James upgraded Dyne Therapeutics from Outperform to Strong Buy and set a new price target of $35.00

    8/25/25 8:07:36 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Karnani Vikram

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    12/23/25 4:08:03 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Karnani Vikram

    3 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    12/23/25 4:05:04 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & President Cox John sold $55,157 worth of shares (2,662 units at $20.72), decreasing direct ownership by 1% to 196,877 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    12/5/25 4:11:49 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & President Cox John gifted 40,000 shares and bought $911,000 worth of shares (100,000 units at $9.11), increasing direct ownership by 42% to 202,179 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    7/15/25 5:11:40 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & President Cox John bought $1,057,216 worth of shares (32,000 units at $33.04) (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    9/4/24 5:42:18 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kersten Dirk bought $29,999,988 worth of shares (1,714,285 units at $17.50) (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    1/11/24 4:31:55 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Leadership Updates

    Live Leadership Updates

    View All

    Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors

    BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the appointment of Carlo Incerti, M.D., to its Board of Directors, effective January 1, 2026. Dr. Incerti is a highly accomplished executive with a strong background in medicine and over 35 years of strategic experience in the biopharmaceutical industry. "Carlo's appointment comes at a pivotal moment for Sparrow as we are looking ahead to pivotal trials of clofutriben for type 2 diabetes and seeking to expand development into other cardiometabolic indications," said Robert Jacks, Sparrow President and Chief Executive Officer. "Carlo is respected globally for

    2/2/26 8:30:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics Appoints Vikram Karnani to Board of Directors

    WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Vikram Karnani to its Board of Directors. Mr. Karnani brings extensive commercial and executive leadership experience in rare disease and biopharmaceuticals, serving as the current chief executive officer of Collegium Pharmaceutical and having spent nearly a decade leading several lines of business and functions at Horizon Therapeutics. "We are pleased to welcome Vikram to our Board as we advance toward commercialization," said Jason

    12/23/25 7:30:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics Appoints Brian Posner to its Board of Directors

    WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Brian Posner to its Board of Directors. Mr. Posner brings 35 years of executive, investment and board leadership expertise to the company. "Brian is joining our Board during a pivotal phase, as we transition to becoming a fully integrated biotechnology company poised to commercialize our first potential product in 2027," said Jason Rhodes, chairman of Dyne's Board of Directors and partner at Atlas Venture. "With a perspective shaped b

    10/2/25 4:05:00 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Financials

    Live finance-specific insights

    View All

    Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

    - Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p<0.0001), replicating the same 7-fold change from baseline previously observed at the registrational dose - - Functional improvement was observed across multiple clinical endpoints at 6 months in REC; lung function was preserved at 6 months - - New positive long-term results from DELIVER trial showed sustained functional improvement across all assessed endpoints through 24 months - - Continued favorable safety and tolerability profile - - Submission for U.S. Accelerated Approval on track for Q2 2026 - - Investor even

    12/8/25 6:30:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET

    WALTHAM, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it plans to announce topline clinical results from the Registrational Expansion Cohort (REC) of the Phase 1/2 DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) on December 8, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event. Investor Conference Call and WebcastThe webcast will be available on the Events & Presentations page of the Investors & Medi

    12/7/25 11:00:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

    - Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from Phase 1/2 ACHIEVE trial support vHOT as early indicator of clinical benefit with DYNE-101 in DM1 - - Ongoing Registrational Expansion Cohort in ACHIEVE trial to enroll 60 participants and include sites in U.S. - - Company to host an investor and analyst conference call today, June 17, at 8:00 a.m. ET - WALTHAM, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically

    6/17/25 7:00:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Dyne Therapeutics Inc.

    SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)

    11/14/24 5:46:12 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dyne Therapeutics Inc.

    SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)

    11/14/24 4:32:40 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dyne Therapeutics Inc.

    SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)

    11/14/24 4:23:11 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care